搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
oncnursingnews
1 天
FDA Approves Isatuximab Plus VRd for Newly Diagnosed Myeloma
The FDA approved isatuximab plus bortezomib, lenalidomide, and dexamethasone for patients with newly diagnosed myeloma who ...
oncnursingnews
1 天
ESR1 Testing Is Crucial in Second-line HR+, HER2- Metastatic Breast Cancer
During a Community Case Forum series, breast cancer experts discussed the importance of testing for ESR1 mutations, in ...
oncnursingnews
1 天
NKT2152 Shows Promising Efficacy in Advanced Clear Cell Kidney Cancer
NKT2152, a novel HIF2a inhibitor, demonstrates significant efficacy in patients with advanced clear cell renal cell carcinoma ...
oncnursingnews
4 天
FDA Approves Adjuvant Ribociclib Plus AI Therapy for HR+, HER2- Breast Cancer
The Food and Drug Administration approved ribociclib plus an aromatase inhibitor for hormone receptor (HR)–positive, ...
oncnursingnews
2 天
Nivolumab With or Without Ipilimumab Sustains 10-Year Survival Benefit in Advanced Melanoma
Nivolumab (Opdivo), when given alone or in combination with ipilimumab (Yervoy), led to significant benefit in 10-year ...
oncnursingnews
3 天
Breastfeeding Is OK During Endocrine Therapy Break for HR+ Breast Cancer
Breastfeeding is feasible for patients with hormone receptor–positive breast cancer who are undergoing a break of endocrine ...
oncnursingnews
4 天
Lung Cancer Trial Falls Short of Goal, But Presents Clinical Benefit in Some Patients
While none of the experimental combinations met efficacy targets, durvalumab with monalizumab and ceralasertib showed ...
oncnursingnews
2 天
FDA Approves Amivantamab-Chemo Combo for Advanced NSCLC
The FDA approved amivantamab-vmjw plus chemotherapy for locally advanced or metastatic non–small cell lung cancer (NSCLC) that harbors EGFR exon 19 deletions or exon 21 L858R substitution mutations ...
oncnursingnews
4 天
Amivantamab Plus Chemo Trends Toward Long-Term Benefit in Advanced NSCLC
Amivantamab plus chemotherapy delivered promising OS trends compared with chemotherapy in EGFR-mutant advanced non-small cell ...
oncnursingnews
8 天
Postsurgical Durvalumab Does Not Boost DFS in Lung Cancer
Adjuvant durvalumab failed to improve disease-free survival in resected EGFR- or ALK-negative non-small cell lung cancer.
oncnursingnews
10 天
Connecting Patients With Multiple Myeloma to Larger Institutions for CAR T-Cell Therapy
Oncology nurses at local and specialized centers can work together to create a pathway for patients throughout CAR T-cell ...
oncnursingnews
5 天
Hypofractionated Radiation Noninferior for Lymphedema Prevention in Early Breast Cancer
For patients with early breast cancer, hypofractionated radiation was noninferior to normofractionated radiation regarding ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果
反馈